Wilson Therapeutics appoints Erik Penser as liquidity provider

Wilson Therapeutics AB (publ) has appointed Erik Penser Bankaktiebolag as
liquidity provider for the company’s share which is listed in the Mid Cap
segment on Nasdaq Stockholm.
This undertaking means in brief that the liquidity provider will set continuous
bid and offer prices for Wilson Therapeutics’ shares with a maximum spread, i.e.
the difference between the bid and offer price, while liquidity will be provided
in the share through a guaranteed minimum volume of shares on the bid and offer
side.
The purpose is to reduce the difference between bid and offer price and increase
the liquidity of the share.
The measures under the undertaking will commence on June 16, 2016.
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden,
that develops novel therapies for patients with rare diseases such as Wilson
Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being
developed as a novel treatment for Wilson Disease and is currently being
evaluated in a Phase II clinical study. Wilson Therapeutics is listed in the Mid
Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information.
For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: jonas.hansson@wilsontx.eu
Wilson Therapeutics AB (publ)
Org nr 556893-0357
Västra Trädgårdsgatan 15
SE-111 53 Stockholm
The information in the press release is such that Wilson Therapeutics is
required to disclose publicly in accordance with the Swedish Securities Market
Act. The information was submitted for publication on June 16, 2016 at 8:00 a.m.